[Chemiluminescence measurement in AIDS, lymphadenopathy and hemophilia patients].
In order to reveal the activity of polymorphonuclear neutrophil leukocytes (PMNL) representing the first step of defence against infections, measurements of chemiluminescence (CL) were performed in patients suffering from acquired immune deficiency syndrome (AIDS), lymphadenopathy, or hemophilia. In comparison with healthy controls, AIDS patients revealed significant reduction (about 50 per cent) of phagocytic, i.e. CL activity of neutrophils, which had been induced by Zymosan. Only part of the patients suffering from lymphadenopathy answered with decreased granulocyte activity on the application of Zymosan. If concanavalin A was used as stimulant of metabolic activity of PMNL-independently of phagocytosis-again AIDS and some of the lymphadenopathy patients showed a markedly reduced neutrophil response. In conclusion it should be stated that there is some evidence for at least two defects of cellular immunity associated with AIDS and to some extent, with AIDS-endangered homosexuals suffering from lymphadenopathy: first the defect of PMNL to answer to concanavalin A with increased metabolic activity, and secondly the defect of PMNL to start phagocytosis induced by Zymosan with a subsequent release of oxygen radicals which are measurable as chemiluminescence. The appraisal of granulocyte activity by means of measurements of chemiluminescence might become an additional criterion for AIDS diagnostics.
Stöhr
L
L
Altmeyer
P
P
Sessler
M J
MJ
Scharrer
I
I
Helm
E B
EB
Holzmann
H
H
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology*; D000212:Acyclovir / Q000627:therapeutic use; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use; D003208:Concanavalin A / Q000494:pharmacology; D004338:Drug Combinations / Q000627:therapeutic use; D006467:Hemophilia A / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D008163:Luminescent Measurements; D008165:Luminol; D008232:Lymphoproliferative Disorders / Q000276:immunology*; D008297:Male; D009504:Neutrophils / Q000276:immunology*; D010587:Phagocytosis; D013420:Sulfamethoxazole / Q000627:therapeutic use; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology; D050378:T-Lymphocytes, Regulatory / Q000166:cytology; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D015054:Zymosan / Q000494:pharmacology
D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D007136:Immunoglobulins; D003208:Concanavalin A; D008165:Luminol; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D015054:Zymosan; D014295:Trimethoprim; D013420:Sulfamethoxazole; D000212:Acyclovir
Chemilumineszenzmessung bei AIDS, Lymphadenopathie- und Hämophiliepatienten.